


THE CANADIAN CHILDREN INFLAMMATORY BOWEL DISEASE NETWORK:
A PARTNERSHIP WITH THE CH.I.L.D FOUNDATION



July 2022 Newsletter

Jump to: [Education Update](#) | [Publications, Awards & Grants](#)



Phase 2 CIDScANN: AMBITION-CD

Assessment of Mucosal Biochemical and clinical response to Interleukin-12/23 or TNF InhibitOrs in biologic-Naïve Crohn’s Disease

If such an enrolled patient turns out to have ulcerative colitis or IBD-U rather than Crohn’s disease, they will not be eligible for the AMBITION- CD analysis, and will not continue to be followed in the cohort. For

[Subscribe](#)

[Past Issues](#)

[Translate ▼](#)

anti-TNF or UST for luminal Crohn's disease
 Participating sites: All
 Target: 200 anti-TNF, 100 UST

Contact: Michelle
michelle.ouzounis@sickkids.ca Contact:
 Hayley hayley.mackay@sickkids.ca

Phase 2 enrolment into a prospective cohort of children and adolescents anticipated to initiate biologic therapy for luminal inflammatory Crohn's disease has begun.

As discussed at the investigator meetings, when patients are willing to provide biopsies for research, we **encourage enrolment prior to diagnostic (or reassessment) scope**, based on investigator conviction that Crohn's disease will be confirmed and that biologic therapy for luminal inflammatory Crohn's disease will be initiated early.

biospecimens collected at the time of enrolment.

We hope that this does not happen often, but we will be able to track occurrences by comparing enrolment numbers and ZOHO registrations when first dose of anti-TNF or ustekinumab is given to AMBITION-CD cohort patients.

Site	Enrolled in AMBITION-CD	Biologic	
		Ustekinumab	Anti TNF
Toronto	13	5	8
London	1	1	0
Edmonton	4	1	3
Halifax	2	0	2
St Johns	1	0	1
Winnipeg	1	0	1
Total	22	7	15

Ongoing Follow-up of Inception Cohort Study

- Inclusion criteria: Children age 2-17y with IBD
- Participating sites: All
- Contact: Michelle michelle.ouzounis@sickkids.ca

Dual biologics (via Main Prevalent Cohort Study)

- Inclusion criteria: Children age 2-17y with IBD on 2 concurrent biologics
- Participating sites: All
- Enrolled: 13
- Contact: Wael welmatary@exchange.hsc.mb.ca

Predictors of response to anti-TNF therapy (Biomark study)

- Inclusion criteria: Children age 2-17y with luminal IBD starting first anti-TNF without prior surgery nor significant stenotic/penetrating disease requiring surgery in short-term

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

- Participating sites: Toronto, Ottawa, Halifax
- Contact: Amanda Amanda.ricciuto@sickkids.ca
- Contact: Shantel Shantel.mangroo@sickkids.ca

Implementing a Multimodal Intervention to Improve the Transition of Patients with Inflammatory Bowel Disease from Pediatric to Adult Care

- Inclusion criteria: Aged 16-17.5 y with IBD, ability to provide informed consent, ability to speak/read English at a Grade 8 level, intention to reside in Canada after transfer to adult care, access to smartphone/computer (can be purchased for the participant if this is a barrier to participation)
- Target: 115
- Enrolled: 28
- Participating sites: Toronto, Ottawa, McMaster, BCCH
- Contact: Eric eric.benchimol@sickkids.ca



Upcoming session:

NOVEMBER 1, 2022 3:00pm- 4:30pm EST

Thromboprophylaxis in Pediatric Inflammatory Bowel Disease

Recent session:

June 28, 2022: The role of bowel ultrasound in pediatric IBD

Missed it? No problem! Listen to the recording at cidscann.ca/education

Learn more & register

We encourage you to share the Education Session calendar invites with your multidisciplinary teams. Please find the dates for future sessions, and past recordings at cidscann.ca/education

Educate



"Early TNF-antagonist Maintenance Therapy Results in Better Outcomes than Immunomodulators in Paediatric Crohn's Disease: A Multi-Centre Prospective Cohort Study"

Lead author: Rilla E. Schneider
PIBD Congress 2022 Oral Presentation

"One-year Outcomes with Ustekinumab Therapy in Paediatric Crohn's Disease: A Prospective Multicenter Cohort Study"

Lead author: Jaclyn Strauss
PIBD 2022 Congress Poster Presentation

6th INTERNATIONAL SYMPOSIUM ON PAEDIATRIC INFLAMMATORY BOWEL DISEASE
September 7-10, 2022 (www.pibdcongress.org)

Check out the Invited Oral Presentations by CIDsCaNN Members:

- Microbiome research: fundamental for IBD and so much more - Eytan Wine
- The lure of 'Big Data': health clinical and administrative data use in IBD research - Eric Benchimol
- Running a nationwide prospective IBD cohort: top tips - Thomas Walters
- Developing and using IBD disease activity scores, QoL scores and PROMs - Anthony Otley
- Commonly used PIBD classifications and scores - Anne Griffiths
- Can genetics help with the selection of medications? - Alex Muise
- How to choose and sequence biologicals and new small molecule drugs in IBD - Anne Griffiths
- PSC-IBD - Amanda Ricciuto
- Epidemiology guide to IBD aetiology - Eric Benchimol

Subscribe

Past Issues

Translate ▾

· PIBD cancer risk: disease or drug - Eytan Wine



Thank you for your engagement and contribution to CIDSCANN!

Website: www.cidscann.ca | Email: info@cidscann.ca

PARTICIPATING SITES



Copyright © 2022 Canadian Children Inflammatory Bowel Disease Network, All rights reserved.

Our mailing address is:

555 University Avenue, Toronto ON Canada M5G 1X8

tel: 416-813-1500

email: info@cidscann.ca

Subscribe

Past Issues

Translate ▼

Want to change how you receive these emails?

You can update your preferences or unsubscribe from this list.

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

CIDScANN · 555 University Ave · Toronto, ON M5G 1X8 · Canada

Grow your business with  **mailchimp**